We are a leading, clinical-stage stem cell business. Our primary objective is the development of novel stem cell therapies targeting areas of significant unmet or poorly met medical need.

We have used our unique stem cell technologies to develop cell-based therapies for significant disease conditions where the cells can be readily administered "off-the-shelf" to any eligible patient without the need for additional drug treatments. Our lead stem cell therapeutic candidates are ReN001, a therapy for the treatment of patients left disabled by a stroke and ReN009, a therapy for critical limb ischaemia. Both treatments are currently in clinical development. We are also developing stem cell therapies for other conditions such as blindness-causing diseases of the retina.

Most recently we have made considerable progress with our exosome platform. Exosomes are nanoparticles secreted into the culture media during the expansion of our stem cells. They contain a number of biologically active molecules such as proteins and miRNAs which may have therapeutic benefits across a number of disease areas.

Our principal strategy is to gain clinical validation for our cell therapy programmes via well-designed clinical trials in well-regulated territories. Ultimately, we expect to realise value for our technologies and therapeutic programmes via out-license to commercial development partners at the appropriate points in their development. In order to achieve these objectives, we work closely with a number of key academic and industrial partners while continuing to maintain tight control over our financial resources.

Our shares are traded solely on the London AIM market under the symbol RENE.L. There are no restrictions on the transfer of the company’s securities. ReNeuron is subject to the UK City Code on Take overs and Mergers